{
  "question_stem": {
    "en": "A physician research group is evaluating the efficacy of a new lipid-lowering drug, Superstatin, which is being marketed directly to consumers as a groundbreaking new therapy to prevent heart attacks. The drug manufacturer claims that the drug is more effective than existing hypolipidemic agents for primary prevention of myocardial infarction. Results of a 5-year, randomized, double-blinded, controlled study to evaluate the efficacy of Superstatin are shown below.\n\n|                  | Number of patients treated with Superstatin | Number of patients treated with control medication |\n|------------------|--------------------------------------------|--------------------------------------------------|\n| Myocardial infarction | 10                                         | 25                                               |\n| No myocardial infarction | 990                                        | 975                                              |",
    "zh": "一个医生研究小组正在评估一种新的降脂药物Superstatin的疗效，该药物直接向消费者销售，声称是一种预防心脏病发作的开创性新疗法。该药物制造商声称，该药物在预防心肌梗死方面比现有的降脂药更有效。评估Superstatin疗效的为期5年的随机、双盲、对照研究结果如下所示。\n\n|                  | Superstatin治疗的患者人数 | 对照药物治疗的患者人数 |\n|------------------|--------------------------------------------|--------------------------------------------------|\n| 心肌梗死 | 10 | 25 |\n| 无心肌梗死 | 990 | 975 |"
  },
  "question": {
    "en": "Compared to the control medication, how many patients need to be treated with Superstatin to prevent one additional myocardial infarction?",
    "zh": "与对照药物相比，需要用Superstatin治疗多少患者才能预防一次额外的心肌梗死？"
  },
  "options": {
    "A": {
      "en": "2",
      "zh": "2"
    },
    "B": {
      "en": "5",
      "zh": "5"
    },
    "C": {
      "en": "23",
      "zh": "23"
    },
    "D": {
      "en": "48",
      "zh": "48"
    },
    "E": {
      "en": "67",
      "zh": "67"
    },
    "F": {
      "en": "92",
      "zh": "92"
    },
    "G": {
      "en": "100",
      "zh": "100"
    }
  },
  "correct_answer": "E",
  "explanation": {
    "en": "The number needed to treat (NNT) represents the number of patients that need to be treated with a medication (eg, Superstatin) in order to prevent an additional negative outcome (eg, myocardial infarction). NNT is calculated by dividing 1 by the absolute risk reduction (ARR).\n\nNNT = 1 / ARR\n\nARR represents the actual difference in control and experimental group event rates. The data is not presented in the standard format of a contingency (2 × 2) table, so care should be exercised in selecting the appropriate values. In this example, the event of interest is myocardial infarction. There were 25 + 975 = 1,000 patients in the control group; of those, 25 had a myocardial infarction. Similarly, there were 10 + 990 = 1,000 patients in the treatment (ie, Superstatin) group; of those, 10 had a myocardial infarction. Therefore:\n\nControl event rate = 25 / 1,000 = 0.025\nExperimental event rate = 10 / 1,000 = 0.01\n\nARR can then be calculated:\n\nARR = Control event rate – Experimental event rate = 0.025 – 0.01 = 0.015, or 1.5%\nFinally, NNT is found by dividing 1 by 0.015:\n\nNNT = 1 / 0.015 = 66.6 ≈ 67\n\nRounding up the result to the nearest whole number, 67 patients need to be treated with Superstatin to prevent an additional myocardial infarction.\n\nThe ideal NNT would be 1, meaning that all patients in the treatment group benefit from the treatment. A low NNT implies that a treatment is more beneficial because fewer patients need to be treated to prevent an additional negative outcome. For instance, if a third hypolipidemic medication had an NNT of 40, it would be more beneficial than Superstatin, as only 40 patients would need to be treated over a given period to prevent an additional myocardial infarction.\n\nEducational objective: The number needed to treat (NNT) is the number of patients that need to be treated with a medication to avoid an additional negative outcome. NNT is calculated by dividing 1 by the absolute risk reduction (the difference between the control and experimental group event rates). Lower NNT values represent more beneficial treatments.",
    "zh": "需要治疗数 (NNT) 代表需要用药物（例如，Superstatin）治疗的患者人数，以预防额外的负面结果（例如，心肌梗死）。 NNT 通过将1除以绝对风险降低 (ARR) 来计算。\n\nNNT = 1 / ARR\n\nARR代表对照组和实验组事件发生率的实际差异。 数据未以列联表（2 × 2）的标准格式呈现，因此在选择适当值时应谨慎。 在此示例中，感兴趣的事件是心肌梗死。 对照组有 25 + 975 = 1,000 名患者； 其中，25人患有心肌梗死。 同样，治疗组（即 Superstatin）有 10 + 990 = 1,000 名患者； 其中，10 人患有心肌梗死。 因此：\n\n对照组事件发生率 = 25 / 1,000 = 0.025\n实验组事件发生率 = 10 / 1,000 = 0.01\n\n然后可以计算ARR：\n\nARR = 对照组事件发生率 – 实验组事件发生率 = 0.025 – 0.01 = 0.015，或 1.5%\n最后，通过将1除以0.015来计算NNT：\n\nNNT = 1 / 0.015 = 66.6 ≈ 67\n\n将结果四舍五入到最接近的整数，需要用Superstatin治疗67名患者以预防额外的心肌梗死。\n\n理想的NNT将为1，这意味着治疗组的所有患者都将受益于治疗。 较低的NNT意味着治疗更有益，因为需要治疗更少的患者以预防额外的负面结果。 例如，如果第三种降脂药的NNT为40，则它将比Superstatin更有益，因为在给定的时间段内只需要治疗40名患者以预防额外的心肌梗死。\n\n教育目标：需要治疗数 (NNT) 是需要用药物治疗以避免额外负面结果的患者人数。 NNT通过将1除以绝对风险降低（对照组和实验组事件发生率之间的差异）来计算。 较低的NNT值代表更有益的治疗方法。"
  },
  "summary": {
    "en": "This question tests knowledge of calculating the number needed to treat (NNT) based on clinical trial data. NNT is an important measure of therapeutic efficacy and is used to determine the number of patients that need to be treated with a medication to prevent one additional negative outcome.\n\nTo solve this question, first calculate the absolute risk reduction (ARR) by subtracting the event rate in the treatment group from the event rate in the control group. Then, divide 1 by the ARR to obtain the NNT. Round the result to the nearest whole number.",
    "zh": "这个问题考察了根据临床试验数据计算需要治疗数 (NNT) 的知识。 NNT是治疗效果的重要指标，用于确定需要用药物治疗多少患者才能预防一个额外的负面结果。\n\n要解决这个问题，首先通过从治疗组的事件发生率中减去对照组的事件发生率来计算绝对风险降低 (ARR)。 然后，用1除以ARR以获得NNT。 将结果四舍五入到最接近的整数。"
  },
  "tags": "Number needed to treat; NNT; Absolute risk reduction; ARR; Therapeutic efficacy; Clinical trials; Biostatistics",
  "category": "Bio",
  "question_id": "1174",
  "has_exhibits": true,
  "exhibit_count": 1,
  "exhibit_files": [
    "image1.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Bio & Statistics 23\\1174",
  "extracted_at": "2025-11-05T10:27:42.201272",
  "translated_at": "2025-11-07T15:44:40.646972",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}